Compare · DXCM vs SRTS
DXCM vs SRTS
Side-by-side comparison of DexCom Inc. (DXCM) and Sensus Healthcare Inc. (SRTS): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DXCM and SRTS operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- DXCM is the larger of the two at $31.08B, about 810.2x SRTS ($38.4M).
- DXCM has been more active in the news (13 items in the past 4 weeks vs 5 for SRTS).
- DXCM has more recent analyst coverage (25 ratings vs 8 for SRTS).
- Company
- DexCom Inc.
- Sensus Healthcare Inc.
- Price
- -
- -
- Market cap
- $31.08B
- $38.4M
- 1M return
- -5.08%
- -
- 1Y return
- +42.43%
- -
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2005
- 2016
- News (4w)
- 13
- 5
- Recent ratings
- 25
- 8
DexCom Inc.
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom G7, a next generation G7 CGM system; and Dexcom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop next-generation CGM products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.
Sensus Healthcare Inc.
Sensus Healthcare, Inc. manufactures, distributes, and markets superficial radiation therapy devices to healthcare providers worldwide. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates the embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters. The company also provides SRT-100 Plus; Sculptura product, a proprietary modulated robotic brachytherapy oncology therapy system that uses patented Beam Sculpting capabilities to treat various cancers during surgery; and Sentinel service program, which offers its customers protection for their systems. In addition, it sells disposable lead shielding replacements; and disposable radiation safety items, such as aprons, eye shields, and disposable applicator tips, which are used to treat various sized lesions and various areas of the body. Sensus Healthcare, Inc. was incorporated in 2010 and is headquartered in Boca Raton, Florida.
Latest DXCM
- EVP Chief Legal Compliance Off Brown Michael Jon covered exercise/tax liability with 1,451 shares, decreasing direct ownership by 1% to 96,734 units (SEC Form 4) to cover withholding tax
- EVP, COO & CFO Sylvain Jereme M covered exercise/tax liability with 1,451 shares, decreasing direct ownership by 0.99% to 145,377 units (SEC Form 4) (for tax liability)
- EVP Chief People & Culture Off Stern Sadie covered exercise/tax liability with 1,451 shares, decreasing direct ownership by 1% to 119,462 units (SEC Form 4) to satisfy withholding obligation
- President, CEO, and Director Leach Jacob Steven covered exercise/tax liability with 1,451 shares, decreasing direct ownership by 0.35% to 417,457 units (SEC Form 4) to satisfy withholding tax
- Dexcom Announces Upcoming Conference Presentation
- SEC Form SCHEDULE 13G filed by DexCom Inc.
- Director Ashley Euan A. gifted 2,389 shares (SEC Form 4)
- Dexcom Invites the Global Diabetes Community to Share Their Stories Through A Letter to Diabetes Campaign
- SEC Form 10-Q filed by DexCom Inc.
- SEC Form 8-K filed by DexCom Inc.
Latest SRTS
- SEC Form 10-Q filed by Sensus Healthcare Inc.
- Sensus Healthcare Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Sensus Healthcare Reports Third Quarter 2026 Financial Results and Business Highlights
- Sensus Healthcare Announces Sale of 1,000th SRT System, Marking Significant Commercial Milestone
- Sensus Healthcare to Report Third Quarter 2026 Financial Results and Hold Business Update Conference Call on November 12, 2026
- Director Sachetta Eric bought $225,616 worth of shares (64,841 units at $3.48), increasing direct ownership by 28% to 294,784 units (SEC Form 4)
- Director Sachetta Eric bought $66,682 worth of shares (20,633 units at $3.23), increasing direct ownership by 10% to 229,943 units (SEC Form 4)
- Director Sachetta Eric bought $112,904 worth of shares (34,697 units at $3.25), increasing direct ownership by 20% to 209,310 units (SEC Form 4)
- CHIEF EXECUTIVE OFFICER Sardano Joseph C bought $60,486 worth of shares (20,000 units at $3.02), increasing direct ownership by 2% to 1,220,293 units (SEC Form 4)
- Director Sachetta Eric bought $97,850 worth of shares (31,000 units at $3.16), increasing direct ownership by 22% to 174,613 units (SEC Form 4)